Radiopharm Theranostics (ASX:RAD) secured approval from the Data and Safety Monitoring Committee (DSMC) to proceed to the next dose in its first phase clinical trial for radiotherapeutic asset 177Lu-RAD204 in patients with PD-L1 positive advanced cancers, according to a Tuesday filing with the Australian bourse.

The DSMC confirmed the safety, pharmacokinetic, and biodistribution data of the first group of four patients treated with 30 millicurie of 177Lu-RAD204, allowing the study to continue without modifications, the filing said.

The second group will start at 60 millicurie of Lu177, expected to enroll by the middle of the year, and expand to multiple tumor types, according to the filing.